Disclosed are a compound for forming a conjugate with an active agent such as an oligonucleotide having a structure represented by Formula (321), and a corresponding conjugate. The conjugate can specifically target hepatocytes, thereby effectively solves the problems associated with delivery of oligonucleotide drugs in vivo, and has low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.